# Trevor Martin

> Trevor Martin is the co-founder and CEO of Mammoth Biosciences, the CRISPR company he built alongside Nobel laureate Jennifer Doudna and two of her graduate students. A Princeton-trained computational biologist who earned his PhD at Stanford, Martin turned a cold email to Doudna into a $465M-funded platform company developing ultracompact CRISPR systems - including NanoCas, the first efficient extrahepatic gene editor - aimed at permanently curing genetic diseases.

- **Role:** Co-Founder and CEO at Mammoth Biosciences
- **Organizations:** Mammoth Biosciences, Princeton University (alumnus), Stanford University (alumnus), Bio-X Stanford
- **From:** Atlanta, Georgia, United States
- **Nationality:** American
- **Education:** BA, Biology (Integrated Science Program), Princeton University, PhD, Biology (Fraser Lab, computational genomics), Stanford University
- **Known for:** Co-founded Mammoth Biosciences with Nobel laureate Jennifer Doudna, raising over $465M total, Secured FDA Emergency Use Authorization for DETECTR BOOST SARS-CoV-2 - the first CRISPR-based high-throughput COVID-19 test (2021), Closed $1B+ strategic collaboration with Bayer for in vivo CRISPR therapies

## Career timeline

- **2007-2011** — Undergraduate at Princeton University in the Integrated Science Program; awarded top honor for senior thesis in molecular biology
- **2011-2017** — PhD student at Stanford University under Hunter Fraser (Biology) and Susan Holmes (Statistics); NSF fellowship recipient; developed statistical methods to study gene expression variation
- **2017** — Co-founded Mammoth Biosciences with Jennifer Doudna, Janice Chen, and Lucas Harrington
- **2020** — Mammoth raises $45M Series C; DETECTR COVID-19 diagnostic launched
- **2021** — FDA Emergency Use Authorization for DETECTR BOOST SARS-CoV-2 test (first CRISPR-based high-throughput COVID test); Mammoth raises $195M Series D
- **2021** — Named EY Entrepreneur of the Year; featured on Forbes 30 Under 30 (healthcare) and Fortune 40 Under 40
- **2023** — Bayer strategic collaboration for in vivo CRISPR gene-editing therapies, potentially valued at over $1 billion
- **2024** — Regeneron collaboration announced to develop in vivo gene editing therapies using Mammoth's ultracompact CRISPR systems; company raises $100M Series E (April 2024)
- **2025-01** — Mammoth announces NanoCas - first efficient ultracompact extrahepatic gene editor; achieves up to 30% editing in skeletal muscle of non-human primates
- **2025-05** — Preclinical data on in vivo gene editing of skeletal muscle presented at ASGCT 2025 in New Orleans

## Achievements

- Co-founded Mammoth Biosciences with Nobel laureate Jennifer Doudna, raising over $465M total
- Secured FDA Emergency Use Authorization for DETECTR BOOST SARS-CoV-2 - the first CRISPR-based high-throughput COVID-19 test (2021)
- Closed $1B+ strategic collaboration with Bayer for in vivo CRISPR therapies
- Collaboration with Regeneron for extrahepatic gene editing
- Led development of NanoCas - the first efficient ultracompact extrahepatic gene editor (2025)
- Forbes 30 Under 30 - Healthcare honoree
- Fortune 40 Under 40
- EY Entrepreneur of the Year 2021
- Malaria No More '10 to END' innovator
- NSF fellowship recipient at Stanford
- Princeton University top honors for senior thesis in molecular biology
- Bio-X Bowes Fellow at Stanford

## Latest updates

- **2025-05** — Mammoth Biosciences presented preclinical data on in vivo gene editing of skeletal muscle in non-human primates at ASGCT 2025 in New Orleans
- **2025-01** — Mammoth Biosciences announced NanoCas - described as the first efficient ultracompact extrahepatic gene editor, achieving up to 30% editing efficiency in cynomolgus macaque skeletal muscle
- **2024-04** — Mammoth Biosciences raised $100M Series E round (April 2024) and announced Regeneron collaboration for in vivo gene editing therapies

## Links

- Website: https://mammoth.bio
- LinkedIn: http://www.linkedin.com/in/trevormmartin
- Twitter/X: https://twitter.com/mammothbiosci
- Facebook: https://facebook.com/mammothbiosci/

---

Profile page: https://yespress.io/trevor-martin
Published by YesPress — https://yespress.io
Last updated: 2026-05-11